Track topics on Twitter Track topics that are important to you
The brokerage currently has a "market outperform" rating on the biopharmaceutical company's stock. JMP Securities' price objective indicates a potential upside of 55.26% from the company's current price.
CPhI Worldwide, organized by UBM EMEA, announces the upcoming trends in the 8th edition of the CPhI Pre-Connect Congress, taking place on October 3rd. The platform brings together experts and thought leaders from the entire pharmaceutical industry to provide insights on the major developments in the industry, with innovation, contract services and patient centricity taking centre stage this year.
People who experience job loss, divorce, death of a loved one or any number of life's upheavals often adopt coping mechanisms to make the situation less traumatic. While these strategies manifest as behaviors, a Princeton University and National Institutes of Health study suggests that our response to stressful situations originates from structural changes in our brain that allow us to adapt t...
The price for a two-pack of EpiPen has gone from less than $100 to over $600 in just a few years. This time it's Heather Bresch of Mylan Laboratories who's explaining why the price for an EpiPen 2-Pak has gone from about $100 to nearly $600 in just a few years.
A number of institutional investors have modified their holdings of the company. EQIS Capital Management raised its position in shares of Sinovac Biotech by 6,472.2% in the fourth quarter.